If you've heard that weight-loss drugs eat muscle, you're right to wonder whether lifting weights helps. In a 2026 Nature Medicine trial report, adults on tirzepatide (the active ingredient in Zepbound) who lifted weights three times a week lost less lean tissue than those on the drug alone. Lifting reduced that loss. It did not prevent it.
The study followed 120 adults aged 50 to 70 at a single centre for 40 weeks. All of them took tirzepatide, and about half also did supervised weight training three times a week. Both groups lost about the same amount of weight. The lifters lost about 1.1 kg less lean tissue, and they got stronger while the drug-only group got weaker.
Disclosure: Before you read on, this page contains affiliate links. Buying through them may earn us a commission.
Quick facts from the trial
These figures are as of 2026-11-20, from the trial report and Nature's coverage.
| Item | Detail |
|---|---|
| Study | T-REx, a single-centre, open-label randomized controlled trial in Nature Medicine, 2026 |
| Who took part | 120 community-dwelling men and postmenopausal women aged 50 to 70, mean age 57.7 |
| Groups | 61 on tirzepatide alone; 59 on tirzepatide plus supervised resistance training |
| Drug | Tirzepatide, stepped up toward 15 mg weekly |
| Length | 40 weeks, with three supervised resistance sessions a week |
| Weight loss | 22.61 kg vs 22.28 kg, no difference (P=0.694) |
| Total lean soft tissue lost | 4.67 kg on the drug alone vs 3.57 kg with training (difference 1.09 kg, 95% CI 0.43 to 1.75) |
| Strength | Fell in the drug-alone group and rose in the training group |
| Session adherence | 91% |
| Serious adverse events | Six in total, 5 vs 1 between the groups; five judged unrelated to tirzepatide and one unrelated to the drug or the exercise |
| Funding | Eli Lilly supplied the drug and reviewed the protocol and draft manuscript |
What the trial found
Nature published a research highlight on the trial on November 20, 2026, under the headline “Lifting weights reduces muscle loss from obesity drugs.” Its line is that “Weightlifting can partially prevent the muscle loss caused by some obesity drugs.” The word that matters is “partially.”
Lean soft tissue fell by 4.67 kg on the drug alone and by 3.57 kg with lifting. Appendicular (limb) lean mass fell by 3.55 kg on the drug alone and by 2.92 kg with lifting, a difference of 0.63 kg. Fat mass showed no significant difference between the groups.
Strength is where the groups split most clearly. Here is how each strength test changed, as reported:
| Strength test | Drug alone (change, kg) | Drug plus lifting (change, kg) |
|---|---|---|
| Bench press | -4.09 | +4.68 |
| Lat pulldown | -4.42 | +8.58 |
| Knee extension | -4.42 | +5.88 |
Lean tissue is not the same as muscle
The trial estimated lean soft tissue with a DXA scan. That number is not the same as muscle. Strength tests show what your body can actually do. In this trial, strength went up with lifting and down without it.
Who was in the study, and who it fits
If you are in your fifties or sixties and new to the gym, you look most like the people studied. They were men and postmenopausal women aged 50 to 70, with a BMI of 30 or higher, or 27 or higher with a health condition. They were previously sedentary, and none had diabetes or heart disease. The Nature highlight says the findings may apply to middle-aged and older adults.
The study does not cover people with diabetes or heart disease, anyone younger than 50 or older than 70, semaglutide (the drug in Ozempic and Wegovy), or other weight-loss drugs. It also tested supervised sessions, not home workouts. Walking is a separate topic from lifting, and our guide on how long should you walk for weight loss covers it.
This is one trial of 120 people, so use it to shape your questions with your prescriber, not as a promise about your own body.
What did not change
Weight loss was the same in both groups. Cardiometabolic markers improved similarly in both groups too, and lifting added no extra benefit to them. If your main goal is weight loss, the trial found no extra gain from lifting. If your goal is strength, that is where the trial saw the difference.
What the trial's authors list as limits
- There was no non-incretin placebo arm and no weight-matched group that did not exercise.
- The design was open-label, so everyone knew which group they were in.
- Lean mass was estimated with DXA. The study did not use MRI.
- Participants were middle-aged or older, without diabetes or heart disease, and initially sedentary.
- The authors say the feasibility of the training in routine care still needs to be established, and long-term effects are unknown. The study ran for 40 weeks.
- Diet was only assessed in a post hoc subset of participants.
Risks to weigh next to the benefits
Six serious adverse events were reported during the trial. The investigators judged five unrelated to tirzepatide and one unrelated to the drug or the exercise. The drug's prescribing information lists more.
| Zepbound label item | What it lists |
|---|---|
| Boxed warning | Thyroid C-cell tumors |
| Warnings | Severe GI reactions, acute pancreatitis, acute gallbladder disease, acute kidney injury, hypoglycemia, hypersensitivity, diabetic retinopathy complications, pulmonary aspiration |
The Zepbound prescribing information says it is approved, with a reduced-calorie diet and activity, to reduce excess body weight and maintain weight loss in adults with obesity, or with overweight plus a related health condition. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro, which also contains tirzepatide, is approved for type 2 diabetes.
The label's warnings include diabetic retinopathy complications. For more on that, see ozempic and zepbound vision loss warning.
Common mix-ups
- “Obesity drugs” vs one drug. The headline and the research highlight say “obesity drugs,” but the trial tested only tirzepatide.
- Lean mass vs muscle. The scan measured lean soft tissue. Strength is the functional result.
- Supervised gym sessions vs home workouts. The lifting was supervised, three times a week.
- Protein and calories. Diet was only assessed in a post hoc subset, so the findings are about lifting and the drug, not a diet plan.
Questions to bring to your prescriber
Whether to start, continue or change Zepbound is a decision you make with your prescriber. For the wider picture, see GLP-1 questions before starting. Bring these questions to that conversation:
- Given my health history, is a resistance training plan safe for me?
- Should I have a strength test before I begin, so we can track changes?
- Which muscle or strength changes should I report to you?
- Does my heart, blood pressure or joint history change what kind of lifting makes sense?
- How would a lifting plan fit with my current treatment plan?
If you have a health condition, check with your clinician before you start any new exercise.
By the New Life Wellness Guide Editorial Team